RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC)

Akshintala Srivandana; Dombi Eva; Glod John; Fox Elizabeth; Lodish Maya; Whitcomb Patricia; Balis Frank; Widemann Brigitte

首页> 外文期刊>Pediatric blood & cancer >RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC)

【24h】

RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC)

机译：甲状腺髓样癌（MTC）患儿对酪氨酸激酶抑制剂（TKI）vandetanib的应答和耐药

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric blood & cancer》 |2015年第2期|共1页
作者
Akshintala Srivandana; Dombi Eva; Glod John; Fox Elizabeth; Lodish Maya; Whitcomb Patricia; Balis Frank; Widemann Brigitte;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC) [J] . Akshintala Srivandana, Dombi Eva, Glod John, Pediatric blood & cancer . 2015,第Suppla2期

机译：甲状腺髓样癌（MTC）患儿对酪氨酸激酶抑制剂（TKI）vandetanib的应答和耐药
2. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor [J] . Park Inkeun, Lee Jae-Lyun, Ahn Jin-Hee, Cancer chemotherapy and pharmacology. . 2015,第5期

机译：同时使用VEGFR-TKI和mTOR抑制剂治疗转移性肾细胞癌患者的血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKI）再挑战
3. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients [J] . C. Resteghini, S. Cavalieri, D. Galbiati, Best practice & research:Clinical endocrinology & metabolism . 2017,第3期

机译：酪氨酸激酶抑制剂（TKI）副作用在分化和髓质甲状腺癌患者中的副作用
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Distinct roles for members of the trk neurotrophin receptor family in the biology of medullary thyroid carcinoma. [D] . McGregor, Lisa MacNabb. 1998

机译：trk神经营养蛋白受体家族成员在甲状腺髓样癌生物学中的不同作用。
6. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience [O] . Marc R. Matrana, Tharakeswara Bathala, Matthew T Campbell, -1

机译：一线帕唑帕尼治疗后再行血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKI）或雷帕霉素抑制剂（mTORi）靶向治疗的未选患者转移性透明细胞肾细胞癌患者的疗效：单一机构经验
7. Re:‘‘Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors’’ [O] . Plaza Menacho Ivan, Groot Jan Willem de, Links Thera, 2004

机译：回复：‘酪氨酸激酶抑制剂抑制甲状腺髓样癌（MTC）细胞增殖和RET磷酸化’”

RESPONSE AND RESISTANCE TO THE RECEPTOR TYROSINE KINASE INHIBITOR (TKI) VANDETANIB IN PEDIATRIC PATIENTS WITH MEDULLARY THYROID CARCINOMA (MTC)

著录项

相似文献

相关主题

期刊订阅